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ABSTRACT
Introduction Antimicrobial resistance is a growing 
global health threat, driven by increasing inappropriate 
use of antimicrobials. High prevalence of unnecessary 
use of antimicrobials in residential aged care facilities 
(RACFs) has driven demand for the development and 
implementation of antimicrobial stewardship (AMS) 
programmes. The Stepped- wedge Trial to increase 
antibiotic Appropriateness in Residential aged care 
facilities and model Transmission of antimicrobial 
resistance (START) will implement and evaluate the impact 
of a nurse- led AMS programme on antimicrobial use in 12 
RACFs.
Methods and analysis The START trial will implement 
and evaluate a nurse- led AMS programme via a stepped- 
wedge cluster randomised controlled trial design in 
12 RACFs over 16 months. The AMS programme will 
incorporate education, aged care- specific treatment 
guidelines, documentation forms, and audit and feedback 
strategies that will target aged care staff, general 
practitioners, pharmacists, and residents and their 
families. The intervention will primarily focus on urinary 
tract infections, lower respiratory tract infections, and 
skin and soft tissue infections. RACFs will transition from 
control to intervention phases in random order, two at a 
time, every 2 months, with a 2- month transition, wash- in 
period. The primary outcome is the cumulative proportion 
of residents within each facility prescribed an antibiotic 
during each month and total days of antibiotic use per 
1000 occupied bed days. Secondary outcomes include 
the number of courses of systemic antimicrobial therapy, 
antimicrobial appropriateness, antimicrobial resistant 
organisms, Clostridioides difficile infection, change in 
antimicrobial susceptibility profiles, hospitalisations and 
all- cause mortality. Analyses will be conducted according 
to the intention- to- treat principle.
Ethics and dissemination Ethics approval has been 
granted by the Alfred Hospital Human Research Ethics 
Committee (HREC/18/Alfred/591). Research findings will 
be disseminated through peer- reviewed publications, 
conferences and summarised reports provided to 
participating RACFs.
Trial registration number NCT03941509.
INTRODUCTION
Antimicrobial resistance has been identified 
as a global public health emergency, linked to 
increasing unnecessary use of antimicrobials. 
Residential aged care is a unique and chal-
lenging setting with high infection burden,1 
high prevalence of inappropriate antimicro-
bial use2 and antimicrobial resistance3 4 in an 
increasingly frail population with complex 
care needs.5
The prevalence of antibiotic use over 
a 12- month period has been reported in 
up to 45%–79% of residents in the USA 
(1991–2009),2 Canada (1994–2004),2 UK 
(2016–2017)6 and in up to 70% of residents 
in Australian residential aged care facilities 
Strengths and limitations of this study
 ► A multifaceted antimicrobial stewardship (AMS) 
programme will be implemented across 12 metro-
politan and regional residential aged care facilities 
(RACFs).
 ► The stepped- wedge randomised controlled design 
enables the robust evaluation of the intervention 
while ensuring all residents are eligible to receive its 
potential benefits.
 ► Data will be collected monthly for each resident and 
supplemented with longitudinal biospecimen sam-
pling over 16 months.
 ► Staff may be employed at more than one trial site 
and become exposed to the intervention earlier than 
the scheduled timeframe.
 ► Substantial engagement with aged care staff and 
consumers will facilitate delivery of a tailored AMS 
programme suitable for broader implementation 
across the RACF network.
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(RACFs) (2005–2017).7 8 Up to 70% of antimicrobials 
are prescribed for infections that do not meet established 
criteria for appropriateness.2 9 10 High levels of inappro-
priate prescribing increases the likelihood of colonisation 
with multidrug- resistant organisms found in up to 50% 
of residents,4 11 with the potential for transmission across 
healthcare settings without adequate infection control.4 12
Antimicrobial stewardship (AMS) programmes are well- 
established in hospitals internationally, contributing to 
reductions in antimicrobial usage and resistance, duration 
of hospitalisation and drug expenditure.13 Although there 
is a need for the integration of AMS programmes in RACFs, 
few established programmes exist. In 2019, the Australian 
Government Aged Care Quality and Safety Commission 
introduced new quality standards requiring all RACFs to 
incorporate AMS in their care and quality improvement 
frameworks.14 Individual RACFs are responsible for the 
development of their own policies and processes to support 
appropriate antimicrobial use and infection control.14 15 
Successful implementation of AMS programmes is particu-
larly challenging in RACFs and is limited by several barriers, 
including workload, staffing levels and composition, on- site 
availability of pharmacists and the complexity of diagnosing 
infections in older people with cognitive impairment.16–18 
AMS interventions have primarily targeted nursing staff 
and medical practitioners in RACFs through increased 
education and promotion of clinical practice guidelines.19 
Nursing staff are consistent members of an RACF workforce 
and hold an important role in influencing antimicrobial 
prescribing decisions, including the initial assessment of 
infection and referral.20 This provides an opportunity for 
nurse- led interventions to drive improvements in appro-
priate antimicrobial use.21 22
Aged care- specific guidance is available to support 
the development and implementation of AMS in 
RACFs.15 23–25 Recommendations have included educa-
tion, guidelines and improving documentation to reduce 
unnecessary investigations and antimicrobial prescribing 
for common infections, including urinary tract infections 
(UTIs), lower respiratory tract infections (LRTIs), and 
skin and soft tissue infections (SSTIs).23 24 Guidelines 
have primarily targeted aged care staff and incorporated 
minimum criteria for antibiotic initiation to assist in the 
initial assessment of signs and symptoms for suspected 
infections.26 27 However, the acceptability, feasibility and 
effectiveness of these tools in reducing inappropriate 
antimicrobial prescribing in RACFs remains unclear.
Several systematic reviews have identified multifaceted 
AMS interventions in RACFs, frequently incorporating 
education, guidelines, and audit and feedback.19 28–31 To 
date, six randomised controlled trials (RCTs) have been 
performed in the USA and/or Canada,32–34 the UK35 
and Sweden.34 Although five studies reported significant 
reductions in antimicrobial use32 34–36 or inappropriate 
antimicrobial prescribing,37 the heterogeneity of inter-
vention components and outcomes limits their compa-
rability to determine successful components of an AMS 
programme.28 No RCTs evaluating the effectiveness of a 
multifaceted AMS programme in Australian RACFs have 
been published.
The Stepped- wedge Trial to increase antibiotic Appro-
priateness in Residential aged care facilities and model 
Transmission of antimicrobial resistance (START) will 
implement and evaluate the impact of a multifaceted 
nurse- led AMS programme on antimicrobial use in 
Australian RACFs.
METHODS AND ANALYSIS
Trial design and setting
The START trial is a multicentre stepped- wedge cluster 
RCT (SW- cRCT) that will see the implementation of a 
nurse- led AMS programme across 12 RACFs in Victoria, 
Australia. As part of the participatory action cycle for 
complex interventions,38 the intervention bundle will be 
piloted and evaluated for feasibility and acceptability over 
a 3- month period in two Victorian RACFs. Consumers 
will review resources targeting residents and families 
prior to commencement. Qualitative feedback from rele-
vant stakeholders, including aged care staff, residents 
and their families, at its conclusion will inform tailoring 
of the intervention prior to the implementation of the 
SW- cRCT. Aged care staff in this protocol refers to regis-
tered nurses (RNs), enrolled nurses (ENs) and personal 
care attendants (PCAs)/assistants in nursing (AINs).
The SW- cRCT will be performed over 16 months 
(figure 1). Each cluster (two RACFs) will transition 
through three phases at 2- month intervals: control; transi-
tion; and intervention. All RACFs will commence the trial 
in the control phase where usual care will continue to 
be provided. The transition phase will involve education 
of staff, residents and family members, and integration 
of the intervention. The intervention phase will see the 
implementation of the AMS programme.
The START trial is registered with  ClinicalTrials. gov . 
This protocol has been written in accordance with the 
Standard Protocol Items: Recommendations for Inter-
ventional Trials 2013 guidelines (online supplemental 
file 1)39 and will be conducted in accordance with the 
Figure 1 Stepped- wedge cluster randomised controlled trial 
design. RACF, residential aged care facility.
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Consolidated Standards of Reporting Trials extension for 
SW- cRCT.40
Randomisation and recruitment
Twelve RACFs with a minimum of 50 residents will 
be selected from a large, private network of RACFs in 
Victoria, Australia. This includes 10 metropolitan and 2 
regional RACFs comprising an average of 100 residents 
per facility. Facilities will be randomised to different 
starting times for the intervention phase (see figure 1 
for timings of steps) prior to commencement using a 
computer- generated random sequence performed by an 
independent statistician. Staff and residents at the RACFs 
will be blinded to their allocation sequence until they are 
made aware of their time to transition from the control 
phase by the study coordinator.
Data will be collected from all residents’ medical and 
medication records over the length of the trial. This 
includes permanent residents and residents receiving 
short- term or respite care admitted to the RACF at any 
point during the trial. Residents will also be invited to 
participate in the biospecimen sampling component.
Intervention bundle
The bundled nurse- led AMS programme incorporates 
education, guidelines, documentation forms, and audit 
and feedback to support appropriate antimicrobial use 
in RACFs (table 1). The intervention will target three 
common infections in RACFs: UTIs, LRTIs and SSTIs.
Education will comprise 1- hour face- to- face presenta-
tions with case studies, an equivalent online resource and 
summary fact sheets. Topics will include inappropriate 
antimicrobial use, antimicrobial resistance, AMS and 
strategies to improve appropriate antimicrobial use in 
RACFs. Face- to- face education will be provided to all aged 
care staff. A web- based resource with equivalent content 
will be available for staff unable to attend. General prac-
titioners (GPs) and pharmacists will be provided with 
the online resource and summary fact sheets specific to 
their role in AMS. Residents and families will be engaged 
via monthly meetings and/or discussion forums and 
provided with fact sheets. Education will be delivered by 
the study coordinator who is a research pharmacist.
Guidelines for the three targeted infections will include 
flowcharts of signs and symptoms required to meet 
minimum criteria for initiation of antibiotics, and recom-
mendations for antimicrobial management. Signs and 
symptoms will be adapted from aged care- specific guidance 
from existing guidelines, including minimum criteria for 
initiation of antibiotics by Loebs et al,26 McGeers criteria 
for infection surveillance10 and the Australian Thera-
peutic Guidelines.41 Hard copy and electronic guidelines 
will be available for all aged care staff, GPs and pharma-
cists to support consistent decision- making.
Assessment criteria and antimicrobial management 
plans will be documented by aged care staff and GPs, 
respectively, on hard copy or equivalent electronic docu-
mentation forms in the residents’ medical record to aid 
the communication of treatment decisions. Antimicro-
bial management plans will include the indication, dose, 
frequency, route and duration of therapy. The assessment 
criteria are primarily targeted towards aged care staff to 
assist in initial assessment of infections prior to GP referral 
Table 1 START intervention bundle components
Component Focus Format Target
Education Common infections: UTIs, LRTIs and SSTIs Face- to- face presentation Aged care staff
Inappropriate antimicrobial use and impact on 
AMR
Online workbook GPs
AMS in aged care Case studies Pharmacists
Assessment of common infections and 
appropriate investigations
Fact sheets Residents and 
families
Guidelines Assessment and management of UTIs, LRTIs 
and SSTIs
One page, double- sided flowcharts Aged care staff
Minimum signs and symptoms for antibiotic 
initiation
Electronic and hard copy GPs
Empirical antimicrobial management Pharmacists
Communication Communication of assessment and 
antimicrobials management of UTIs, LRTIs and 
SSTIs











*Hard copy forms will be adapted for integration into electronic medical records where necessary.
AMR, antimicrobial resistance; AMS, antimicrobial stewardship; GP, general practitioner; LRTIs, lower respiratory tract infections; SSTIs, 
skin and soft tissue infections; START, Stepped- wedge Trial to increase antibiotic Appropriateness in Residential aged care facilities and 
model Transmission of antimicrobial resistance; UTI, urinary tract infections.
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and antimicrobial prescribing. The management guide-
lines are targeted towards both aged care staff and GPs 
to encourage timely review of antimicrobial prescribing 
and improve overall knowledge of current antimicrobial 
recommendations.
Audit and feedback is a common and effective strategy 
to drive quality improvement and change prescribing 
behaviour.42 Prescribing data collected by the research 
team will be analysed and provided to GPs and aged 
care staff on a monthly basis. This summarised data will 
include monthly antimicrobial prescription rates and 
their appropriateness against the intervention criteria. 
This feedback will serve to benchmark prescribing at indi-
vidual RACFs against all participating trial sites to drive 
continued improvements in appropriate prescribing.
Trial procedure
Usual care will be provided to residents during the control 
phase. Standard care provided by pharmacists, including 
medication reviews, will continue over the trial. Although 
a formal AMS programme will not be available for staff 
during the control phase, a small proportion of staff may 
be exposed to the intervention at other participating or 
non- participating RACFs. An assessment of aged care 
staffing, GPs and pharmacists who provide care at trial 
sites will be performed prior to trial initiation to identify 
the proportion of staff crossover.
During the transition phase, the research team will liaise 
with each RACF to coordinate education and delivery of 
the intervention bundle over 2 months. Attendance of 
aged care staff at education sessions will be designated as 
mandatory by the aged care provider to increase aware-
ness and understanding of intervention procedures. Staff 
unable to attend will be followed up with additional face- 
to- face education and/or referred to the online resource. 
All aged care staff, GPs and pharmacists will have access to 
the intervention resources via a password- protected trial 
website during the transition and intervention phases. 
Guidelines and documentation forms will be placed in 
high- visibility areas across nursing stations in RACFs to 
increase accessibility and encourage uptake. Ongoing 
education will be provided during the intervention phase 
at regular intervals, depending on staff turnover and 
need. The intervention procedure will be incorporated 
in each facility’s standard operating procedures.
Aged care staff who care for residents with suspected 
UTIs, LRTIs and/or SSTIs will be directed to the rele-
vant guideline to assess symptoms against the specified 
signs and symptoms of infection. If the resident meets the 
minimum criteria for antimicrobial prescribing, the GP 
will be contacted to review and perform further investi-
gations as necessary. The guidelines do not replace clin-
ical judgement and staff are instructed to contact the GP 
if they are concerned or the resident is acutely unwell. 
Assessments are documented on the corresponding form 
or entered electronically if electronic medical records are 
in place. Although final review and completion of assess-
ment forms are performed by an RN, as PCAs comprise 
70% of the aged care workforce,43 initial suspicion of an 
infection and subsequent tests (eg, urinalysis) are likely to 
be performed by PCAs. Antimicrobial management plans 
may be documented by the GP or aged care staff member.
A key liaison person or ‘champion’ in each RACF who 
is a RN will be responsible for reinforcing the continued 
use of intervention resources at their facility.
Data collection and monitoring
Deidentified data will be collected from each resident’s 
medical records and medication charts by trained research 
assistants within the trial team monthly during the control 
and intervention phases (table 2). Baseline resident char-
acteristics will be collected on enrolment, including demo-
graphic and clinical characteristics, advance care directives, 
prior hospitalisations and antimicrobial use. Monthly resident 
data will include clinical characteristics (eg, catheter use and 
mobility), suspected infections, microbiology results, systemic 
antimicrobial use, hospitalisations, transfer to other RACFs, 
discharge (in the case of respite) and death. In the case of 
a suspected infection, documented diagnoses and investiga-
tions performed by aged care staff and/or the treating team, 
including radiology, urinalysis and urine, blood, sputum, 
nasal/throat and wound cultures, will be collected from 
each resident’s medical record. Microbiology results include 
findings of drug- resistant organisms and susceptibility to anti-
microbials. Antimicrobials include all systemic antibiotics, 
antifungals and antivirals, and their name, dose, frequency, 
duration, indication and appropriateness. Signs and symp-
toms of infection (eg, fever and cough) documented prior to 
commencement of antimicrobial prescribing will be assessed 
against the minimum criteria specified in the intervention 
guidelines. The appropriateness of antimicrobials will be 
assessed in two ways: (1) initial prescribing meets minimum 
signs and symptoms required for initiation as stated in the 
intervention assessment guidelines; (2) initial prescribing 
(type and dose) aligns with recommended guidance provided 
in the Australian Therapeutic Guidelines.
Baseline facility characteristics will be obtained from 
management staff at each facility on commencement of the 
trial, including occupancy, presence of specialist dementia 
care units, permanent and casual staffing (RN, EN, PCA/
AIN, GP and pharmacy) and infectious diseases education 
and practices.
All data will be entered directly into a secure web- based 
data entry system. Each resident will be assigned a unique 
study identity document (ID) to remain unidentifiable 
outside the facility. Random audits and statistical monitoring 
of data (5%–10% random sample) will be conducted by the 
research team throughout the trial to assess the accuracy 
and completeness of data. As the trial involves standard care 
and the collection of non- invasive biospecimen collection, 
adverse events are not anticipated.
Qualitative and quantitative feedback will be obtained 
from relevant stakeholders, including aged care staff, GPs, 
pharmacists, and residents and their families, to inform revi-
sions to the intervention bundle following the pilot and trial. 
Semistructured one- on- one interviews and focus groups, 
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performed by an external qualitative researcher, and an 
online questionnaire will be used to explore participants’ 
awareness, acceptability and impact of the intervention.
Biospecimen sampling
Residents, or their guardians, who have verbally consented 
to participate in biospecimen sampling will have nasal, 
rectal and/or a wound specimen taken monthly over a 
12- month period in each RACF. Consent and collection 
will be performed by trained research nurses. Wound 
samples will only be obtained in the case of an active 
infection treated with an antimicrobial. Residents at each 
facility will be sampled a minimum of 2 months prior and 




Resident follow- up (month)
Close- 
outEnrolment Allocation Enrolment
Enrolment -t2 -t1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 16 
months
Facility eligibility screen and recruitment X                                   
Facility allocation X                                   
Resident eligibility screen and enrolment X X X X X X X X X X X X X X X X X
Interventions
AMS programme*   
Control (usual care)   
Assessments
Facility assessment
  Facility characteristics (occupancy 
and speciality units)
X                                 
  Staffing (nursing, medical and 
pharmacy)
X                                 
  Infectious disease education and 
practices
X                                 
Baseline resident assessment†
  Demographic and clinical 
characteristics
X                                 
  Prior antimicrobial use X                                 
  Prior hospitalisations X                                 
Advance care directives X                                 
Monthly resident assessment
Clinical characteristics   X X X X X X X X X X X X X X X X
  Suspected infections‡   X X X X X X X X X X X X X X X X
  Diagnoses   X X X X X X X X X X X X X X X X
  Investigations§   X X X X X X X X X X X X X X X X
  Microbiology
  AMR organisms   X X X X X X X X X X X X X X X X
  Antimicrobial susceptibility   X X X X X X X X X X X X X X X X
  Systemic antimicrobial use
  Administration
  (dose, route and duration)
  X X X X X X X X X X X X X X X X
  Indication   X X X X X X X X X X X X X X X X
  Appropriateness¶   X X X X X X X X X X X X X X X X
Hospitalisation   X X X X X X X X X X X X X X X X
Transfer to another facility, home or 
death
  X X X X X X X X X X X X X X X X X
Biospecimen collection**
  Nasal, rectal±wound specimen   X X X X X X X X X X X X X X X X
*Excluding the transition (‘wash- out’) phase.
†Baseline resident characteristics will be performed for all new residents over the 16- month trial.
‡Suspected infections include urinary tract infections, respiratory tract infections, skin and soft tissue infections, and Clostridioides difficile infections.
§Investigations include radiology, urinalysis and urine, sputum, nasal/throat, rectal/faecal, wound and blood cultures.
¶Appropriateness is assessed according to minimum signs and symptoms for initiation of antimicrobials as specified in the intervention bundle, and antimicrobial recommendations as 
per the Australian Therapeutic Guidelines.
**Specific timing to be determined.
AMR, antimicrobial resistant; AMS, antimicrobial stewardship.
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post transition. Specimens will be cultured in a microbi-
ology laboratory to identify antimicrobial- resistant organ-
isms. Changes to facility- level susceptibility profiles will 
be examined over the duration of the trial by the START 
research team and feedback provided back to RACFs. A 
detailed procedure manual for biospecimen sampling 
will be developed and published separately.
Outcome measures
Primary outcomes
Two approaches were selected to provide different 
perspectives to the assessment of our primary outcome of 
antibiotic use. These include the cumulative proportion 
of residents within each facility prescribed an antibiotic at 
any point during each calendar month of the trial and the 
rate of total days of systemic antibiotic use per 1000 occu-
pied bed days (OBD). The number of days of therapy per 
1000 OBD is a widely used and recommended measure of 
antibiotic use in residential aged care.7 19 44
All systemic antibiotics will be included according to the 
second level of the WHO Anatomical Therapeutic Chem-
ical (ATC) classification system for antibacterials (J01).45 
Antibiotics will be included irrespective of documented 
indication, including those outside of the targeted UTIs, 
LRTIs and SSTIs.
Secondary outcomes
Secondary outcomes include the number of courses of 
systemic antimicrobial therapy per 1000 OBD, proportion 
of appropriate antimicrobial use, frequency of carriage of 
multidrug- resistant organisms, rate of Clostridioides difficile 
infection, change in facility- level antimicrobial suscepti-
bility profiles, incidence of resident transfers to hospital 
due to infection and all- cause mortality.
All systemic antimicrobials will be included according 
to the second level of the WHO ATC classification system 
for antibacterials (J01), antimycotics (J02), antimyco-
bacterials (J04) and antivirals (J05).45 Antimicrobials 
will be included irrespective of documented indication, 
including those outside of the targeted UTI, LRTI and 
SSTIs.
Process evaluation
A mixed- methods approach will be undertaken to assess 
implementation fidelity, sustainability, and procedures 
and processes associated with the programme implemen-
tation. This will be examined through data collected on 
adherence to components of the intervention bundle, 
the quality and complexity of delivery of the intervention, 
and qualitative feedback from aged care staff, GPs, phar-
macists, residents and their families. Qualitative feedback 
will be provided via anonymous online questionnaires, 
moderated focus groups and/or one- on- one interviews. 
These qualitative and quantitative methods will be used 
to measure implementation fidelity by evaluating use 
and compliance with intervention education, guidelines 
and documentation forms (eg, completion of educa-
tion and documentation, and minimum criteria met for 
prescribing), and resulting changes in antimicrobial use 
and appropriateness.
Sample size
Sample size calculations were performed in accordance 
with the approach described by Hemming and Taljaard46 
and the use of summative, facility- month level data. Esti-
mated means and SD were obtained from published 
and unpublished literature examining antimicrobial 
prescribing in Australian RACFs.1 47 48 This includes 
unpublished data from a SW- cRCT in 15 RACFs between 
2011 and 2015 which identified that approximately 21% 
of residents received an antibiotic each month (estimated 
SD of 8%).48 Assuming a between- facility correlation of 
0.01, to achieve greater than 80% power at a 5% signif-
icance level, 12 RACFs across 6 clusters are required to 
demonstrate a relative reduction in the proportion of resi-
dents receiving an antibiotic of 24% (21%–16% postin-
tervention). This effect size is consistent with studies of 
smaller interventions that demonstrated greater than 
20% reductions in antimicrobial use.49 50
Although sufficient data is not available to inform a 
sample size calculation based on the rate of resident- days 
on antimicrobials, power is expected to be greater as this 
endpoint as it also incorporates reductions in concurrent 
antibiotic courses and duration of therapy.
Statistical analysis
Primary outcomes will be analysed using summative 
facility- month level data as an intention- to- treat anal-
ysis. A generalised linear mixed- effects model will be 
performed to assess whether exposure to the interven-
tion has no impact on antibiotic use (proportion or rate 
per 1000 OBDs) within each calendar month. This model 
will include a random effect for RACF, and a categorical, 
fixed effect for each month to account for secular trends. 
Model assumptions will be examined to ensure appro-
priate distributional families and covariance matrices for 
the random effects are employed. Data from the wash- in, 
transition period will be excluded from these analyses as 
we do not consider the data captured within this period 
to be clearly control or clearly intervention phase data.
Secondary outcomes will be analysed with an analogous 
approach. The impact of the intervention on primary and 
secondary outcomes will also be examined for variation by 
‘time from implementation’ to identify delayed behaviour 
change or dissipation in impact over time. Qualitative 
feedback will be analysed using the Capability, Oppor-
tunity, Motivation and Behaviour (COM- B)/Behaviour 
Change Wheel51 and Acceptability52 frameworks.
Patient and public involvement
The research question was informed by national research 
priorities to address antimicrobial resistance in RACFs. The 
trial protocol was designed in collaboration with research 
partners and their associated consumer representatives. 
Feedback from relevant stakeholders, including healthcare 
workers, aged care residents and their families, will inform 
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revisions to all components of the intervention bundle 
following the pilot phase and SW- cRCT. Specific intervention 
bundle components targeting residents and families will be 
reviewed by consumer representatives prior to the pilot. A lay 
summary of findings will be disseminated to aged care staff, 
residents and their families, and relevant consumer groups at 
the conclusion of the trial.
ETHICS AND DISSEMINATION
Ethical approval was obtained from the Alfred Hospital 
Human Research Ethics Committee (HREC) (HREC/18/
Alfred/591). Consent to obtain data from residents’ medica-
tion charts and records was waived. Verbal informed consent 
is required from residents, or a person authorised by law to 
consent on their behalf, for biospecimen sampling. Written 
informed consent from staff and residents and their families 
will be sought to participate in focus groups and interviews 
(online supplemental file 2). Residents will be given a unique 
study ID and deidentified data will be securely stored on web- 
based data entry systems.
Research findings from the START trial will be submitted 
for publication in a peer- reviewed journal and presented at 
relevant conferences. Participating RACFs will be provided 
with a report of summarised research findings, including a 
lay summary for distribution to residents and families.
DISCUSSION
Increasing attention has been directed towards the role of 
RACFs in the transmission of antimicrobial resistance across 
the healthcare system. Despite several aged- care specific 
treatment guidelines and education- centred interventions 
targeting inappropriate prescribing, minimal studies have 
performed high quality clinical trials to examine their effec-
tiveness in clinical practice.
The START trial will evaluate the impact of a nurse- led AMS 
programme on antimicrobial use in RACFs. The stepped- 
wedge design ensures residents are not excluded from the 
potential benefits of this intervention while maintaining the 
robust nature of a RCT. Substantial engagement with key 
stakeholders over the length of the trial will ensure the devel-
opment of a tailored programme that may be rapidly trans-
lated across a broad network of RACFs nationally.
Staff may be employed at more than one trial site and 
become exposed to the intervention earlier than the sched-
uled timeframe. Although it is anticipated that this number 
will be small, an assessment of staff crossover between trial 
sites will be performed prior to commencement to better 
understand this potential risk of bias.
The pilot commenced in August 2019 with the START trial 
due to commence in late 2020/early 2021. Amendments to 
the protocol due to increasing infection control precautions 
during the COVID-19 pandemic may be required and will be 
subject to approval from the Alfred HREC. This may include 
considerations to the mode of delivery of education and 
collection of data by research staff.
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